3 Biocompatibility Testing Pitfalls That Hide Device Risks—Expert Insights to Fix Them

Biocompatibility testing is a critical gatekeeper for medical device safety, yet many teams inadvertently fall into pitfalls that obscure real risks. This comprehensive guide reveals the three most common mistakes—testing the wrong material, ignoring extractable and leachable (E&L) implications, and misapplying ISO 10993 standards. Drawing from real-world scenarios, we explain why each pitfall occurs, how it hides device risks, and—most importantly—how to fix it with actionable strategies. You will learn to align your test plan with clinical exposure, integrate E&L analysis early, and interpret results with expert judgment. Whether you are a regulatory specialist, quality engineer, or R&D lead, this article provides the insights you need to strengthen your biocompatibility program and avoid costly delays. Last reviewed: May 2026.

Why Biocompatibility Pitfalls Persist in Medical Device Development

Biocompatibility testing is often perceived as a checkbox exercise—a series of tests that, once passed, guarantee device safety. In reality, it is a complex, science-driven process that requires deep understanding of materials, chemistry, biology, and regulatory expectations. The stakes are high: a single oversight can lead to patient harm, costly recalls, or regulatory rejection. Yet, despite decades of guidance, the same pitfalls recur across device programs.

The Illusion of a Universal Test Battery

Many teams assume that a standard set of tests—cytotoxicity, sensitization, irritation—will cover all risks. This assumption ignores that biocompatibility is device-specific. A material that is safe in a short-term skin contact device may leach harmful chemicals when implanted for years. For example, a polyurethane used in a wound dressing might release trace plasticizers that are harmless externally but could cause inflammatory responses if the same material is used in a vascular graft. The test battery must be tailored to the device's intended use, contact duration, and patient population.

How the Pitfalls Evolve with Device Complexity

As devices incorporate new materials, coatings, and manufacturing processes, the potential for hidden risks multiplies. Additive manufacturing, for instance, introduces unique surface chemistry and residual monomers that traditional tests may not detect. Similarly, combination products—devices with biological or drug components—require integrated assessments that go beyond standard protocols. Teams that rely on historical test data for similar devices may miss these nuances.

Learning from Near-Misses

In one composite scenario, a team developing a hydrogel-based implant tested the raw polymer for cytotoxicity and passed. However, after gamma sterilization, the hydrogel released new leachables that caused chronic inflammation in animal studies. The team had not considered that sterilization could alter the material's chemical profile. This near-miss delayed the project by nine months and cost significant resources. The lesson: biocompatibility testing must account for the entire lifecycle—from raw material to final sterilized product.

To move beyond checkbox thinking, teams must adopt a risk-based approach. This means starting with a thorough material characterization, mapping the device's clinical exposure, and using that information to design a test plan that targets the most relevant hazards. The pitfalls we will discuss are not failures of the testing methodology itself, but of the planning and interpretation around it.

Pitfall 1: Testing the Wrong Material State

One of the most common yet preventable mistakes is testing a material in a state that does not represent the final device. This pitfall arises from a misunderstanding of what biocompatibility testing is supposed to evaluate: the biological response to the device as it will be used in patients. When the test sample differs from the clinical product—in form, processing, or chemistry—the results can be misleading.

Why Material State Matters: The Case of Surface Chemistry

Consider a device that is manufactured with a silicone oil coating to reduce friction. If the biocompatibility tests are performed on the uncoated silicone substrate, the results will not capture the effects of the oil. The oil might leach into tissue, causing inflammation or granuloma formation. Conversely, the oil could mask an adverse response to the substrate itself. In both cases, the test data is incomplete. A team once tested a catheter's base polymer—a medical-grade polyurethane—and passed all standard tests. However, when used in a clinical trial, patients developed localized irritation. Investigation revealed that a processing aid left on the surface during manufacturing was the culprit. The aid was not present in the test samples because they were prepared differently.

Process-Induced Changes: Sterilization and Aging

Sterilization methods can dramatically alter material properties. Ethylene oxide (EtO) sterilization may leave toxic residues if aeration is insufficient. Gamma radiation can break polymer chains, creating radicals that cross-link or produce new leachables. Teams must test the device after the final sterilization cycle, not before. Similarly, aging—whether real-time or accelerated—can cause degradation that releases particles or chemical species. For implants intended to last years, testing only the fresh device is insufficient. A recent composite example involved a biodegradable scaffold: initial tests showed no toxicity, but after three months of in vitro aging, degradation products triggered a cytotoxic response. The team had to reformulate the polymer.

How to Fix It: A Step-by-Step Approach

First, create a material state matrix that lists every processing step (molding, coating, sterilization, packaging) and identifies how each step might change the material's biocompatibility profile. Second, prepare test samples that match the final device as closely as possible—same geometry, same surface treatments, same sterilization cycle. Third, include worst-case scenarios: test the device after maximum allowed sterilization cycles (e.g., if the label allows two cycles, test after two). Fourth, for long-term devices, incorporate aged samples into the test plan. Finally, document all material state assumptions in the biocompatibility evaluation report. This systematic approach ensures that test results reflect real-world conditions and reduces the risk of hidden surprises.

Pitfall 2: Overlooking Extractables & Leachables (E&L) Until Too Late

Extractables and leachables (E&L) analysis is the process of identifying and quantifying chemical substances that can migrate from a device into the patient. Many teams treat E&L as a separate, optional study—something to do only if a problem arises. This is a significant oversight. E&L data is essential for interpreting biological test results and for supporting regulatory submissions, especially for devices with prolonged patient contact.

The Connection Between E&L and Biological Endpoints

When a cytotoxicity test shows a positive result, the natural question is: what caused it? Without E&L data, the answer is a guess. An extractables profile can pinpoint the offending chemical—perhaps a residual monomer, a plasticizer, or a degradation product—and guide reformulation. Conversely, a negative cytotoxicity test does not guarantee safety if leaching occurs over time. Leachables that appear only after months of implant can cause chronic inflammation or genotoxicity. In one scenario, a team developing a silicone breast implant relied on cytotoxicity data from the cured elastomer. Years later, low-molecular-weight siloxanes were found to migrate into surrounding tissue, triggering an immune response. An early E&L study would have flagged these siloxanes.

Regulatory Expectations Are Growing

Regulatory bodies now expect a comprehensive E&L assessment for many device categories. ISO 10993-18 (chemical characterization) and ISO 10993-17 (toxicological risk assessment) provide frameworks. The FDA's guidance on biocompatibility recommends chemical characterization as a starting point, with biological testing only when chemical data cannot assure safety. Teams that skip or delay E&L may face requests for additional data during review, causing delays. Moreover, E&L data can sometimes substitute for certain animal tests, reducing overall testing burden and cost.

Practical Steps to Integrate E&L Early

Start by conducting a material review: identify all components and their potential chemical constituents. Use literature and supplier data to flag known leachables (e.g., BPA in polycarbonate, phthalates in PVC). Then, perform an extractables study under exaggerated conditions (e.g., high temperature, aggressive solvents) to identify the worst-case chemical release. From these results, conduct a toxicological risk assessment to determine which leachables need quantification in clinical use. Finally, design a leachables study that mimics actual clinical exposure conditions. Integrate these findings into your biocompatibility evaluation report, linking each leachable to its potential biological endpoint. This proactive approach not only reveals hidden risks but also strengthens your regulatory submission.

Pitfall 3: Misapplying ISO 10993 Standards

ISO 10993 is the cornerstone of biocompatibility testing, but it is often misunderstood as a rigid checklist. In reality, the standard is a framework that requires professional judgment. Misapplications include performing unnecessary tests, skipping needed tests, or misinterpreting results. These errors waste resources and can hide genuine risks.

Common Misapplications and Their Consequences

One frequent misapplication is using the wrong test battery for the device's contact type. For example, a device that contacts blood for less than 24 hours (limited exposure) might not need a hemolysis test, but teams sometimes include it out of caution, while omitting a thrombogenicity evaluation that is actually relevant. Another common error is testing in an inappropriate animal model. A dermal irritation test in rabbits may not predict the response in human mucosal tissue. Additionally, teams often misinterpret a negative result as proof of safety for all endpoints, ignoring that a test may not be sensitive to certain risks (e.g., cytotoxicity assays may miss low-level chronic toxicity).

The Role of a Biological Evaluation Plan (BEP)

The solution is to create a Biological Evaluation Plan (BEP) before any testing begins. The BEP documents the device's intended use, contact duration, and patient population. It then maps each biological endpoint (cytotoxicity, sensitization, genotoxicity, etc.) to the relevant ISO 10993-1 table, justifying which tests are needed and which are not. For instance, if the device is a short-term skin-contact bandage, systemic toxicity tests are unlikely needed. But if the device is a long-term implant, tests for chronic toxicity, carcinogenicity, and reproductive toxicity may be required. The BEP should also consider the material's history of safe use—if a material has a long track record in similar devices, some tests can be waived with proper justification.

How to Correctly Apply the Standard

First, assemble a cross-functional team including toxicology, materials science, and regulatory expertise. Second, write a BEP that references ISO 10993-1 and any relevant product-specific guidance (e.g., FDA's 510(k) guidance). Third, for each biological endpoint, decide whether to test, use literature data, or provide a rationale for omission. Fourth, when conducting tests, follow the specific ISO 10993 test methods (e.g., 10993-5 for cytotoxicity, 10993-10 for sensitization) and ensure the testing laboratory is accredited. Finally, interpret results in the context of the device's clinical use—a mild irritation seen in rabbits might be acceptable for a wound dressing but not for an ocular implant. Document all decisions and rationales in the Biological Evaluation Report (BER).

Tools and Frameworks for Robust Biocompatibility Programs

Building a robust biocompatibility program requires more than avoiding pitfalls—it requires the right tools and frameworks. These include risk management software, chemical characterization databases, and structured decision-making processes. Investing in these tools upfront can save significant time and cost.

Essential Tools for Material Characterization

Chemical characterization is the foundation of modern biocompatibility. Tools like Fourier-transform infrared spectroscopy (FTIR), gas chromatography-mass spectrometry (GC-MS), and inductively coupled plasma mass spectrometry (ICP-MS) can identify and quantify chemical constituents. These instruments, while expensive, provide data that can reduce or replace animal testing. For startups, third-party testing labs offer these services at manageable costs. Additionally, online databases (e.g., from FDA or the European Chemicals Agency) can provide toxicological data for common chemicals, aiding risk assessment.

Risk Management Software and Templates

ISO 14971 (risk management for medical devices) requires that biocompatibility risks be identified, analyzed, and controlled. Dedicated risk management software can help track hazards, link them to test results, and maintain a living document. For smaller teams, a well-structured spreadsheet with columns for material, hazard, risk level, mitigation, and verification can suffice. The key is to create a closed-loop system: from risk identification to testing to residual risk acceptance.

Comparison of Biocompatibility Testing Strategies

No single strategy fits all devices. Most programs use a hybrid approach: start with literature and chemical data, then conduct targeted biological tests for gaps. The choice depends on device novelty, regulatory pathway, and budget.

Growth Mechanics: Building a Biocompatibility Knowledge Base

Biocompatibility is not a one-time project—it is a discipline that benefits from continuous learning and improvement. Teams that invest in building internal knowledge and processes can accelerate future projects and reduce risks. This section explores how to create a sustainable biocompatibility program that grows with your organization.

Documenting Lessons Learned

After each device project, conduct a biocompatibility retrospective. What went well? What surprises occurred? Which tests were most informative? Document these insights in a centralized knowledge base. Over time, this repository becomes a powerful resource for guiding new projects. For example, if you learned that a particular plasticizer leaches during steam sterilization, that knowledge can inform material selection for the next device.

Training and Cross-Functional Collaboration

Biocompatibility is not solely the responsibility of a regulatory specialist. Engineers, designers, and manufacturing staff all make decisions that affect biocompatibility. Regular training sessions—even short lunch-and-learns—can raise awareness. Topics might include: how surface roughness affects cell adhesion, why processing aids matter, or how to read a material supplier's biocompatibility certificate. Encourage questions and create a culture where team members feel comfortable raising concerns.

Staying Current with Regulatory Trends

Regulatory expectations evolve. The FDA's Biocompatibility Guidance (issued in 2016 and updated since) emphasizes chemical characterization and reduces reliance on animal testing. The EU MDR requires a more rigorous clinical evaluation. Subscribe to regulatory newsletters, attend webinars, and participate in industry forums. By staying informed, you can anticipate changes and adjust your program before they become urgent.

Metrics to Track Program Health

Consider tracking metrics such as: time from material selection to test completion, number of repeat tests (indicative of poor planning), number of unexpected findings during testing, and regulatory review cycle time. A rising trend in unexpected findings may signal a gap in material characterization. Regularly review these metrics with your team and identify improvement opportunities.

Risks, Pitfalls, and Mitigations in Biocompatibility Programs

Even with the best intentions, biocompatibility programs face risks beyond the three main pitfalls. This section outlines additional common mistakes and how to mitigate them. Awareness of these risks can prevent small issues from becoming major problems.

Over-Reliance on Supplier Data

Material suppliers often provide biocompatibility certificates or test data. However, these tests may have been performed on a different grade, lot, or processing condition. Always verify that supplier data matches your specific material and processing. Request the full test report, not just a summary. In one case, a team relied on a supplier's cytotoxicity pass for a resin, only to find that their own injection molding process introduced a mold release agent that failed the test. The supplier data was valid for the raw resin but not for the final part.

Ignoring the Impact of Packaging

Packaging materials can also leach chemicals into the device, especially during sterilization. For example, adhesives used in pouches may release volatile organic compounds that adsorb onto the device surface. Include packaging in your E&L assessment, particularly for devices that are stored for extended periods. Also consider the device's storage conditions—temperature, humidity, and light can accelerate leaching.

Inadequate Sample Size and Statistical Power

Biocompatibility tests often use small sample sizes (e.g., 3 rabbits for irritation). While this follows standards, it may not capture variability. If a material has batch-to-batch variation, testing only one batch can miss a problem. Consider testing multiple batches, especially for raw materials with known variability. For quantitative assays (e.g., cytotoxicity), use enough replicates to detect meaningful differences.

Mitigation Checklist

• Always verify supplier data against your specific material and process.
• Include packaging materials in extractables testing.
• Test multiple batches if material variability is suspected.
• Conduct a risk assessment for each processing step.
• Document all assumptions and justifications.
• Engage a toxicologist early in the process.

By anticipating these risks and building mitigations into your program, you can avoid many of the common pitfalls that lead to delays and additional costs.

Frequently Asked Questions About Biocompatibility Testing Pitfalls

This section answers common questions that arise when teams try to avoid the pitfalls discussed in this guide. The answers are based on practical experience and current regulatory expectations.

What is the most common mistake teams make when selecting test samples?

The most common mistake is testing a material that is not representative of the final device. This includes using a different geometry, surface finish, or processing state. Always test the final sterilized product with its packaging, if applicable.

How early should I start E&L analysis?

As early as possible—ideally during material selection. Early E&L data can guide material choices and avoid costly reformulation later. Even a screening-level extractables study on candidate materials can provide valuable information.

Can I use literature data instead of testing?

Yes, if the literature data is relevant and sufficient. The material should have a documented history of safe use in a similar device with comparable patient contact. You must provide a rationale and reference the original studies. However, literature data cannot cover all endpoints, especially if your device introduces new risks.

What should I do if a biocompatibility test fails?

First, don't panic. Investigate the root cause: is the failure due to the material, processing, or test artifact? Conduct chemical analysis to identify the offending substance. Then, determine if the material can be reformulated or processed differently. Sometimes, a different sterilization method or a cleaning step can resolve the issue. Document all findings and corrective actions in your risk management file.

How do I choose a testing laboratory?

Look for laboratories that are accredited to ISO 17025 and have experience with your device type. Ask for references and check their turnaround times. Ensure they follow the specific ISO 10993 test methods you need. A good lab will also provide expert interpretation of results, not just raw data.

Is it possible to reduce animal testing?

Yes. Chemical characterization and in vitro tests (e.g., in vitro cytotoxicity, skin sensitization) can replace some animal tests. Regulatory bodies encourage the use of alternative methods when scientifically justified. Start with a chemical assessment and only proceed to animal tests if needed to address specific risks.

Synthesis and Next Actions for a Safer Biocompatibility Program

Biocompatibility testing is not a static requirement but an evolving process that demands vigilance, expertise, and a proactive mindset. The three pitfalls we have covered—testing the wrong material state, overlooking E&L until too late, and misapplying ISO 10993—are common but entirely avoidable. Each one can be addressed through careful planning, cross-functional collaboration, and a commitment to understanding the device's true biological interactions.

Your Immediate Action Plan

1. Audit your current test samples: Compare them to your final device and identify any discrepancies. If you find gaps, create a plan to retest with representative samples.
2. Initiate an E&L assessment: Even a preliminary extractables study can reveal hidden leachables. Use the results to update your risk assessment and test plan.
3. Review your ISO 10993 application: Check that your test battery matches your device's contact type and duration. Ensure your BEP is documented and approved by a toxicologist.
4. Establish a knowledge base: Start documenting lessons learned, supplier data, and test results in a structured format. This will accelerate future projects.
5. Schedule a team training session: Share this article with your team and discuss how these pitfalls apply to your current devices.

Remember that biocompatibility is a shared responsibility. By fostering a culture of curiosity and continuous improvement, your team can not only avoid these pitfalls but also build devices that are safer for patients and more likely to succeed in regulatory review. The investment in a robust biocompatibility program pays dividends in reduced risk, faster timelines, and greater trust from regulators and clinicians alike.